Related Experiment Video

Updated: May 13, 2026

High Efficiency Differentiation of Human Pluripotent Stem Cells to Cardiomyocytes and Characterization by Flow Cytometry
13:13

High Efficiency Differentiation of Human Pluripotent Stem Cells to Cardiomyocytes and Characterization by Flow Cytometry

Published on: September 23, 2014

Growth differentiation factor 15 can distinguish between hypertrophic cardiomyopathy and hypertensive hearts

Shinsuke Hanatani1, Yasuhiro Izumiya, Seiji Takashio

  • 1Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.

Heart and Vessels
|March 26, 2013
PubMed

Insights

Growth differentiation factor 15 (GDF-15) is a promising biomarker for differentiating hypertensive left ventricular hypertrophy (H-LVH) from hypertrophic cardiomyopathy (HCM). Higher GDF-15 levels were observed in H-LVH patients, aiding in distinguishing these conditions.

Area of Science:

  • Cardiology
  • Biomarkers
  • Diagnostic Medicine

Background:

  • Distinguishing hypertrophic cardiomyopathy (HCM) from hypertensive left ventricular hypertrophy (H-LVH) via morphology is challenging.
  • Growth differentiation factor 15 (GDF-15) is an emerging biomarker in cardiovascular diseases.
  • GDF-15 may aid in differentiating HCM from H-LVH in patients with left ventricular hypertrophy (LVH).

Purpose of the Study:

  • To evaluate the utility of serum GDF-15 concentrations in distinguishing between HCM and H-LVH.
  • To compare GDF-15 levels with B-type natriuretic peptide (BNP) in these patient groups.

Main Methods:

  • Serum GDF-15 and plasma BNP levels were measured in 93 H-LVH patients, 28 HCM patients, and 28 controls using enzyme-linked immunosorbent assay.
  • Statistical analyses included comparisons, correlation assessments, multivariate logistic regression, and receiver-operating characteristic (ROC) analysis.

Main Results:

  • Circulating GDF-15 levels were significantly higher in H-LVH patients compared to HCM patients (P=0.003).
  • Plasma BNP levels were significantly lower in H-LVH patients than in HCM patients (P=0.004).
  • GDF-15 was identified as an independent predictor of H-LVH (OR 12.06) with an AUC of 0.70 in ROC analysis.

Conclusions:

  • Serum GDF-15 may serve as a valuable biomarker for discriminating between HCM and H-LVH.
  • Understanding GDF-15 levels has potential clinical utility due to differing therapeutic strategies for HCM and H-LVH.

More Related Videos

In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells09:05

In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells

Published on: August 9, 2017

Generation of First Heart Field-like Cardiac Progenitors and Ventricular-like Cardiomyocytes from Human Pluripotent Stem Cells08:37

Generation of First Heart Field-like Cardiac Progenitors and Ventricular-like Cardiomyocytes from Human Pluripotent Stem Cells

Published on: June 19, 2018

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...